Humanized monoclonal antibody for prevention of respiratory syncytial virus infection

Affiliations

Comment

G A Storch. Pediatrics. 1998 Sep.

. 1998 Sep;102(3 Pt 1):648-51.

doi: 10.1542/peds.102.3.648.

¹ Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, MO 63110, USA.

No abstract available

Comment in

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
[No authors listed] [No authors listed] Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
Comments on palivizumab (Synagis).
Moler FW, Brown RW, Faix RG, Gilsdorf JR. Moler FW, et al. Pediatrics. 1999 Feb;103(2):495-7. doi: 10.1542/peds.103.2.495. Pediatrics. 1999. PMID: 9925848 Clinical Trial. No abstract available.
Questions about palivizumab (Synagis).
Eppes SC. Eppes SC. Pediatrics. 1999 Feb;103(2):534-5; author reply 535-6. Pediatrics. 1999. PMID: 10026068 Clinical Trial. No abstract available.
IMpact-RSV Study Group report.
Zempsky WT, Schechter NL. Zempsky WT, et al. Pediatrics. 1999 Oct;104(4 Pt 1):993-4; author reply 995. Pediatrics. 1999. PMID: 10532865 No abstract available.